ABEONA THERAPEUTICS INC. Impairment of Ongoing Project
ABEONA THERAPEUTICS INC. (ABEO) reported Impairment of Ongoing Project of $3.30 million for the 3-month period ending 2022-03-31, per its 10-Q filed 2022-08-11.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ImpairmentOfOngoingProject · last filed 2022-08-11
- ABEONA THERAPEUTICS INC. impairment of ongoing project for the quarter ending 2022-03-31 was $3.30M.
| Period end | Impairment of Ongoing Project 3 month | Impairment of Ongoing Project 3 month as first filed |
|---|---|---|
| 2022-03-31 | $3.30M 10-Q · filed 2022-08-11 | $3.25M 10-Q · filed 2022-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |